Biohaven achieves positive topline results in pivotal study of troriluzole in spinocerebellar ataxia (sca)

Troriluzole 200 mg dosed orally, once daily, in patients with sca met the study's primary endpoint on the change from baseline in the modified functional scale for the assessment and rating of ataxia (f-sara) at 3 years in all study population genotypes. troriluzole also showed statistically significant superiority after both 1 and 2 years of treatment.
BHVN Ratings Summary
BHVN Quant Ranking